MTOR and neoplasm: A notable number of pathogenic mutations, including those in TP53, NF1, PTEN, MTOR and RB1 were detected, as were a few mutations in POLE and POLD1. There was no clear association between these specific molecular features, including tumor mutational burden, on response to treatment (Table 4 and Supplementary Table 5).